{"organizations": [], "uuid": "76bc37f2731ed852d05769435fec79e211577441", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/18/business-wire-seattle-genetics-to-host-conference-call-and-webcast-discussion-of-fourth-quarter-and-year-2017-financial-results-on.html", "country": "US", "domain_rank": 767, "title": "Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-18T16:00:00.000+02:00", "replies_count": 0, "uuid": "76bc37f2731ed852d05769435fec79e211577441"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/18/business-wire-seattle-genetics-to-host-conference-call-and-webcast-discussion-of-fourth-quarter-and-year-2017-financial-results-on.html", "ord_in_thread": 0, "title": "Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "fourth quarter", "sentiment": "none"}, {"name": "wash.", "sentiment": "none"}, {"name": "bothell", "sentiment": "none"}], "organizations": [{"name": "seattle genetics, inc.", "sentiment": "neutral"}, {"name": "seattle genetics", "sentiment": "neutral"}, {"name": "seattle genetics seattle genetics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:\nLIVE access on Tuesday, February 6, 2018\n1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time\nTelephone 888-778-9065 (domestic) or 719-325-2452 (international); conference ID 9278036 Webcast available at www.seattlegenetics.com in the Investors section\nREPLAY access\nTelephone replay will be available beginning at approximately 4:30 p.m. PT on Tuesday, February 6, 2018 through 5:00 p.m. PT on Friday, February 9, 2018 by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference ID 9278036 Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section\nAbout Seattle Genetics\nSeattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180118005148/en/\nSeattle Genetics, Inc.\nPeggy Pinkston, 425-527-4160\nppinkston@seagen.com\nSource: Seattle Genetics, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Finvestor.seattlegenetics.com%2Fphoenix.zhtml%3Fc%3D124860%26p%3Dirol-IRHome&esheet=51744883&newsitemid=20180118005148&lan=en-US&anchor=Investors+section&index=4&md5=f28ea69a73e26111296dc0c5f43ee0e7", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.seattlegenetics.com&esheet=51744883&newsitemid=20180118005148&lan=en-US&anchor=www.seattlegenetics.com&index=3&md5=6ebeaa4dfe251d2828b4fec317501c7f", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.seattlegenetics.com&esheet=51744883&newsitemid=20180118005148&lan=en-US&anchor=www.seattlegenetics.com&index=5&md5=566ab1b4b8846bcf0f829030892aeb17", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.seattlegenetics.com&esheet=51744883&newsitemid=20180118005148&lan=en-US&anchor=www.seattlegenetics.com&index=1&md5=03623ba20c17c4dafcaf89e9aaccf581", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Finvestor.seattlegenetics.com%2Fphoenix.zhtml%3Fc%3D124860%26p%3Dirol-IRHome&esheet=51744883&newsitemid=20180118005148&lan=en-US&anchor=Investors+section&index=2&md5=eee01f6e45aba2d5dd14ec12ea24c6ca", "http://www.businesswire.com/news/home/20180118005148/en/"], "published": "2018-01-18T16:00:00.000+02:00", "crawled": "2018-01-18T16:28:56.001+02:00", "highlightTitle": ""}